Retatrutide appears to be a new pharmaceutical in the fight against obesity. This novel drug, belonging to a dual GLP-1 and GIP receptor agonist, exhibits promising results in investigations. By activating these receptors, Retatrutide controls cravings, {promotesenergy expenditure, and ultimately leads to significant weight loss. While studies are